PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED + CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

Digitalitzat per Artypla

Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011

RésuméIntroductionCette étude vise à estimer une prévalence de la bronchopneumopathie chronique obstructive (BPCO) traitée et les coûts associés par degré de sévérité.MéthodeElle a été conduite sur les données 2011 de l’échantillon généraliste de bénéficiaires (EGB). Cet échantillon représente 1/97e des bénéficiaires des principaux régimes d’assurance maladie obligatoire. Les cas et leur sévérité ont été identifiés à partir d’algorithmes originaux. Les coûts ont été établis dans une perspective collective.RésultatsLe taux de prévalence minimale de la BPCO traitée a été estimé à 3,8 % dans la population âgée de 40ans et plus, et 1,9 % tous âges confondus. La population (58,2 % d’hommes) avait 68,8±12,7ans d’âge moyen. Au total, 6,2 % des patients ont eu des consommations de soins évocatrices d’un stade très sévère, 8,1 %, 13,8 % et 71,9 % d’un stade sévère, modéré ou peu sévère. Sur une année, 28,8 % ont consulté un pneumologue, 5,0 % ont été hospitalisés (≥24h) pour BPCO et 6,7 % sont décédés. En moyenne, les patients ont eu 1,7±1,5 exacerbations/an et seulement 61,4 % ont reçu un traitement médicamenteux spécifique. La consommation annuelle moyenne de soins d’un patient a été estimée à 9382€ dont 5516€ attribuable à la BPCO.ConclusionCette étude utilisant des bases de données médico-administratives confirme l’importance du fardeau épidémiologique et économique de la BPCO en France.SummaryObjectivesTo estimate the prevalence of treated chronic obstructive pulmonary disease (COPD) and its associated costs by stage of severity.MethodsThe study was conducted on the 2011 data of the french general beneficiary sample database (EGB). EGB is a 1/97th sample of the whole population of the beneficiaries of the main compulsory national health insurances. COPD cases and the level of severity of the disease have been identified using new algorithms established from the available parameters in EGB. Costs were estimated using a collective perspective.ResultsThe minimal prevalence of treated COPD was estimated at 3.8% in patients of 40 years and older and 1.9% regardless of the age of individuals. This population was predominantly male (58.2%) with a mean age of 68.8 years (±12.7). A total of 6.2% of patients had a health-care utilization suggestive of a very severe stage of COPD and 8.1%, 13.8% and 71.9% suggestive of severe, moderate and mild stages respectively. Over one year, 28.8% of patients visited a specialist respiratory physician, 5.0% were hospitalized (≥24h) for COPD and 6.7% died. Patients experienced an average of 1.7 (±1.5) exacerbations per year and only 61.4% received specific pharmacological treatment for COPD during the year. The average yearly health-care cost of a patient with COPD was estimated at €9382, with €5342 directly related to COPD.ConclusionThis study based on medico-administrative databases confirms the high epidemiological and economic burden of COPD in France

Use of re-randomized data in meta-analysis

BACKGROUND: Outcomes collected in randomized clinical trials are observations of random variables that should be independent and identically distributed. However, in some trials, the patients are randomized more than once thus violating both of these assumptions. The probability of an event is not always the same when a patient is re-randomized; there is probably a non-zero covariance coming from observations on the same patient. This is of particular importance to the meta-analysts. METHODS: We developed a method to estimate the relative error in the risk differences with and without re-randomization of the patients. The relative error can be estimated by an expression depending on the percentage of the patients who were re-randomized, multipliers (how many times more likely it is to repeat an event) for the probability of reoccurrences, and the ratio of the total events reported and the initial number of patients entering the trial. RESULTS: We illustrate our methods using two randomized trials testing growth factors in febrile neutropenia. We showed that under some circumstances the relative error of taking into account re-randomized patients was sufficiently small to allow using the results in the meta-analysis. Our findings indicate that if the study in question is of similar size to other studies included in the meta-analysis, the error introduced by re-randomization will only minimally affect meta-analytic summary point estimate. We also show that in our model the risk ratio remains constant during the re-randomization, and therefore, if a meta-analyst is concerned about the effect of re-randomization on the meta-analysis, one way to sidestep the issue and still obtain reliable results is to use risk ratio as the measure of interest. CONCLUSION: Our method should be helpful in the understanding of the results of clinical trials and particularly helpful to the meta-analysts to assess if re-randomized patient data can be used in their analyses

Imaging-guided chest biopsies: techniques and clinical results

Background This article aims to comprehensively describe indications, contraindications, technical aspects, diagnostic accuracy and complications of percutaneous lung biopsy. Methods Imaging-guided biopsy currently represents one of the predominant methods for obtaining tissue specimens in patients with lung nodules; in many cases treatment protocols are based on histological information; thus, biopsy is frequently performed, when technically feasible, or in case other techniques (such as bronchoscopy with lavage) are inconclusive. Results Although a coaxial system is suitable in any case, two categories of needles can be used: fine-needle aspiration biopsy (FNAB) and core-needle biopsy (CNB), with the latter demonstrated to have a slightly higher overall sensitivity, specificity and accuracy. Conclusion Percutaneous lung biopsy is a safe procedure even though a few complications are possible: pneumothorax, pulmonary haemorrhage and haemoptysis are common complications, while air embolism and seeding are rare, but potentially fatal complications